Anbio Biotechnology Class A Ordinary Shares (NNNN) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Anbio Biotechnology (NNNN) 3-Minute Overview > **💡 One-Sentence Summary** > > Anbio Biotechnology is a newly listed German biotech company on Nasdaq that’s already highly profitable but trading at a sky‑high valuation, making it a classic “story stock” where expectations are everything. > **📍 Basic Profile** > > Market Cap **$3.3 billion** · Biotechnology · NASDAQ · Price **$23.03** --- > **⚡ 3 Things You Should Know** > > 1. 💰 **Unusually profitable for biotech:** With gross margin ~70% and net margin ~43%, plus ROE ~34%, this looks more like a mature, cash‑rich tech company than a typical loss‑making biotech — so this is not a “hope it works in Phase 3” story, it’s already making good money. > > 2. 🎢 **Valuation is extreme and expectations are huge:** A **PE over 550** and **PS over 230** imply the market is assuming explosive future growth; at this price, even small disappointments in growth or margins could trigger big drawdowns. > > 3. 🧪 **Growth decent, not hyper, and earnings trend is mixed:** 3‑year revenue growth around **23%** is solid but not crazy; EPS over 3 years is **slightly negative growth**, meaning profitability isn’t clearly ramping — that’s a red flag when the valuation is priced for perfection. --- > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |------------------|---------------------|---------| > | Profitability | Strong💪 | Net margin ~42.5%, ROE ~33.5%, very high vs most biotechs | > | Growth Rate | Steady📈 | 3‑year revenue growth ~22.7%, but EPS down slightly | > | Financial Health | Healthy💚 | Debt to equity 0, current ratio ~10.7, interest coverage ~45 | > | Valuation | Very Expensive | PE ~555x, PS ~236x TTM | --- ## 📋 Layer 2: 2-Minute Deep Dive ### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Sells biotechnology products/services (likely high‑margin diagnostic or specialty products, given margins) to healthcare or lab customers, earning money mainly through product sales rather than just R&D milestones. **Revenue Breakdown:** (Detailed segment data not provided, so we stay high level.) | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Core biotech products/services | [Data unavailable] | ↑ | High margins suggest premium or specialized products | | Other / licensing | [Data unavailable] | [Data unavailable] | May exist but not visible from current data | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |---------------|-----------|----------------|----------------| | Gross Margin | 69.8% | Top tier | Very strong pricing power and/or high value‑add; similar to quality software/diagnostics companies | | Net Margin | 42.53% | Top tier | Converts a huge chunk of revenue into profit; rare in biotech | | Operating Margin | 39.86% | Top tier | Core operations are very efficient; not just an accounting trick | | ROE TTM | 33.53% | Excellent (>20%) | Equity is being used very efficiently to generate profits | In plain language: this is a **high‑margin, high‑return** business right now, not a speculative lab burning cash. --- ### 📈 How's the Growth? **Growth Assessment:** **Steady Growth**, but not “hypergrowth” you’d normally pair with this type of valuation. | Metric | Latest (3Y CAGR) | vs Typical Biotech | Trend | |-----------------|------------------|--------------------|-------| | Revenue Growth | 22.72% | Above average | Healthy, but not 50–60%+ hypergrowth | | EPS Growth | -2.1% | Concerning | Profits per share slightly down over 3 years | **Growth Quality (What this suggests):** - Revenue is growing at a nice clip (~23% CAGR), which is solid for a profitable company. - But **EPS is slightly shrinking**, which can mean: - Costs growing faster than revenue (maybe more R&D, SG&A, or stock comp), or - Share count dilution offsetting profit growth. - When you combine **flat‑to‑down EPS** with an ultra‑high PE, it suggests the market is **looking far beyond recent history**, betting that: - Current high margins are sustainable, and - Growth will accelerate or open new big markets. If growth **doesn’t** accelerate, the current valuation is hard to justify. --- ### 💰 Financial Health Check **One Sentence:** Balance sheet looks like a debt‑free, cash‑rich company that doesn’t need to worry about paying its bills anytime soon. | Metric | Value | Safe Zone | Assessment | |-------------------------|---------|----------------|------------| | Debt to Equity (Annual) | 0 | <60% safe | ✅Safe — virtually no financial leverage | | Current Ratio (Quarterly) | 10.71 | >1.5 healthy | ✅Very Safe — lots of short‑term assets vs liabilities | | Quick Ratio (Annual) | 7.41 | >1.0 healthy | ✅Very Safe — even without inventory, liquidity is high | | Interest Coverage | 44.9 | >3 comfortable | ✅Very Safe — can easily cover any interest costs | So from a **survival** standpoint, this looks robust: no obvious insolvency risk, plenty of liquidity, no meaningful debt burden. --- ### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52‑Week Low: **$5.18** - 52‑Week High: **$55.65** - Current: **$23.03** Position in range: - Distance from low: (23.03 − 5.18) / (55.65 − 5.18) ≈ **35% up from the low** - Distance from high: (23.03 − 5.18) / (55.65 − 5.18) ≈ **about one‑third of the way up the range** Roughly: **in the lower‑middle of its 52‑week band**, and recently down **~15% in a day** (based on the −4.19 move), which hints at some negative sentiment or profit‑taking. | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|-----------|-----------|-------------| | Criteria | 0–33% | 33–66% | 66–100% | | **Current** | | ●(~35%) | | So versus its own 1‑year history, it’s **not at peak euphoria** anymore, but still way above the lows. **Valuation Comparison:** (We only have current TTM multiples, no history/peer averages in the data, so interpret relatively.) | Comparison | Current | Reference | Assessment | |-------------|------------------|-----------------|------------| | PE TTM | ~555x | Many profitable biotechs: 20–40x | Extremely high; priced for very long runway of growth | | PS TTM | ~236x | Quality growth healthcare: often 5–20x | Off the charts; implies massive expectations | | vs Own History | [Data unavailable] | 5‑year avg [n/a] | Recently IPO’d, no long history yet | | vs Peers | [Not given] | Industry avg [n/a] | Qualitatively: dramatically more expensive than “normal” | **What the Current Valuation is Betting On:** - Market seems to be **betting on:** - Sustained very high margins (40%+ net) - Strong and possibly accelerating revenue growth from here - Expansion into big markets and new products - At these multiples, the stock is **not** priced as “maybe it’ll work”; it’s priced as if **success is almost a given** and the company will grow into a much larger business. So the key question for you is: **Do you believe the story can justify this kind of pricing?** --- ### 📰 Any Recent News? The structured data shows **no recent news, no analyst recommendations, no insider transaction records, and no detailed earnings history**. | Date | Event | Impact | |------|-------|--------| | [Data unavailable] | No events in feed | Neutral — either very early post‑IPO, or news coverage is still thin in this dataset | For a name this volatile and richly valued, you’d normally want to track: - Quarterly earnings commentary (growth, margins, guidance) - Any product approvals, trial results, or regulatory news - Capital raises, insider selling, lock‑up expirations post‑IPO Those are missing here, so you’d likely need to cross‑check with other sources. --- ## 📊 Layer 3: Want More? 3-Minute Complete Analysis ### I. Detailed Financial Data (We only have snapshot metrics, not year‑by‑year numbers, so trends are partial.) **Profitability Trends:** (Yearly breakdown not given; only current values.) | Metric | This Year | Last Year | Year Before | 3-Year Trend | |-------------|-----------|-----------|-------------|--------------| | Gross Margin | 69.8% | [n/a] | [n/a] | [Data unavailable] | | Net Margin | 42.53% | [n/a] | [n/a] | [Data unavailable] | | ROE | 33.53% | [n/a] | [n/a] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |---------------|-----------|-----------|-------------|--------------| | Revenue Growth (3Y CAGR) | 22.72% | [n/a] | [n/a] | ↑ — Indicates healthy growth over 3 years | | Profit Growth | [n/a] | [n/a] | [n/a] | [Data unavailable] | | EPS Growth (3Y) | -2.1% | [n/a] | [n/a] | Slight ↓ in EPS over 3 years | So what we *can* say: - Top‑line has compounded nicely. - Bottom‑line per share has **not** tracked that growth, which is not what you want to see for such a pricey name. --- ### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |--------------|--------------|-----------|----------| | [Most Recent] | [n/a] | [n/a] | [Data unavailable] | | [Q‑1] | [n/a] | [n/a] | [Data unavailable] | | [Q‑2] | [n/a] | [n/a] | [Data unavailable] | | [Q‑3] | [n/a] | [n/a] | [Data unavailable] | **Earnings Trend Interpretation:** - The database doesn’t show consensus estimates or actuals, so we **don’t know** if this company tends to beat or miss. - For a high‑expectation growth stock like this, the **pattern of beats/misses often drives the share price** even more than absolute numbers. - You’d want to watch the **first few earnings after IPO** closely — these can reset the market’s narrative. --- ### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |-----------------|-------|------------| | Strong Buy/Buy | [n/a] | [n/a] | | Hold | [n/a] | [n/a] | | Sell | [n/a] | [n/a] | **Target Price:** [Data unavailable] **vs Current Price:** [Data unavailable] **Insider Activity:** No data in the feed for net insider buying/selling in the last few months. > Normally, **heavy insider buying** in a young, profitable, high‑growth name is a good signal that management believes the long‑term story is still undervalued. > Consistent **insider selling**, especially right after lock‑up expiration, can be a yellow flag — not because selling is always bad, but because it shows where management’s risk–reward feels balanced. Right now we simply **don’t see** this information from the dataset. --- ### IV. Key Risk Alerts 1. **Valuation Risk (Biggest one):** PE ~555 and PS ~236 leave almost no room for error → if revenue growth slows, margins compress, or guidance underwhelms, the stock could **re‑rate sharply lower** even if the business is still “good”. 2. **Earnings Quality / Sustainability:** Margins and ROE are *exceptionally* high for biotech → if these are boosted by temporary factors (e.g., one‑off contracts, COVID‑era demand, short‑term pricing power), normalization could significantly reduce profits and make today’s multiples look even richer. 3. **Information & Liquidity Risk (new IPO):** With a recent IPO (2025‑02‑19), there’s **limited public history**, potential for **post‑IPO volatility**, possible **lock‑up expirations**, and fewer analyst models → price can swing a lot on small bits of news or sentiment shifts. Depending on your risk tolerance, these may be acceptable or deal‑breakers. --- ## 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** Anbio Biotechnology is a newly listed, German biotech on Nasdaq that’s already showing tech‑like profitability (high margins, high ROE) with decent revenue growth. > **Key strength:** It combines **strong balance sheet health** (no debt, high liquidity) with **unusually high profitability**, which is rare in this sector. > **Key risk:** The stock is priced at extremely high multiples, so the main risk is **valuation compression** if future growth and margins don’t live up to the very optimistic expectations baked into today’s price. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis of its product, IP, and competitive position. > • Want to check for hidden landmines (lock‑up dates, one‑off earnings, customer concentration)? → Try【Muddy Mode】for risk screening. > • Think of it as a growth rocket and want to see if the numbers can justify it? → Try【Musk Mode】to stress‑test valuation vs different growth scenarios.